Genge, Angela

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., et al. (2022) · New England Journal of Medicine

Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders Research

Cited by 966

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine

Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

Cited by 565

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Bril, V., Drużdż, A., Grosskreutz, J., Habib, A. A., Mantegazza, R., Sacconi, S., Utsugisawa, K., Vissing, J., Vu, T., Boehnlein, M., et al. (2023) · The Lancet Neurology

Myasthenia Gravis and ThymomaPeripheral Neuropathies and Disorders

Cited by 295

Diagnostic Delay in Amyotrophic Lateral Sclerosis

Gwathmey, K. G., Corcia, P., McDermott, C. J., Genge, A., Sennfält, S., de Carvalho, M., & Ingre, C. (2023) · European Journal of Neurology

Amyotrophic Lateral Sclerosis ResearchDementia and Cognitive Impairment Research

Cited by 76